INVO Fertility (IVF) 2nd Annual Lytham Partners Healthcare Investor Summit summary
Event summary combining transcript, slides, and related documents.
2nd Annual Lytham Partners Healthcare Investor Summit summary
15 Jan, 2026Company overview and mission
Focuses on fertility care, operating clinics and leveraging innovative technology.
Operates three clinics and is acquiring a fourth in Indianapolis.
Dual mission: provide patient care and advance fertility technology.
INVOcell device is FDA-cleared and used in company and third-party clinics.
Market landscape and industry trends
U.S. fertility market estimated at $5–$7 billion annually, with about 460 clinics.
Steady market growth, but high treatment costs limit patient access.
Recent government policies aim to improve affordability and drive demand.
Industry increasingly focused on efficiency and expanding clinic networks.
Growth strategy and operational initiatives
Pursues both organic growth and acquisitions to scale operations.
Organic growth driven by outreach, new services, and increased patient flow.
Acquisition pipeline robust, with Indianapolis deal nearing completion.
Long-term growth includes building new clinics, as done in Birmingham and Atlanta.
Latest events from INVO Fertility
- Shareholders will vote on key proposals to expand capital, amend governance, and align incentives.IVF
Proxy filing23 Jun 2026 - Q1 2026 revenue rose 23% to $2.0M, but ongoing losses and funding needs raise going concern risks.IVF
Q1 202622 Jun 2026 - Clinic network expansion and INVOcell innovation drive growth and improved financial outlook.IVF
Planet MicroCap Las Vegas 202617 Jun 2026 - Clinic network and technology-driven growth boost revenue and operational scale.IVF
Corporate presentation17 Jun 2026 - Shareholders are asked to approve director elections, major capital changes, and key governance proposals.IVF
Proxy filing12 Jun 2026 - Revenue up 5% and net loss narrowed as four-clinic network and balance sheet strengthened.IVF
Q4 20252 Jun 2026 - Revenue and EBITDA improved sharply as acquisitions and technology drive clinic growth.IVF
Corporate presentation20 Mar 2026 - Clinic-focused fertility company targets $15M via warrant exercise, risking dilution.IVF
Registration Filing2 Feb 2026 - All proposals passed, enabling key steps in the strategic growth plan for the coming year.IVF
EGM 202622 Jan 2026